NASDAQ:ADROAduro BioTech Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aduro BioTech Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.47 -0.03 (-1.20 %) (As of 08/13/2020 04:00 PM ET) Add Compare Share Today's Range$2.44Now: $2.47▼$2.5750-Day Range$2.18MA: $2.64▼$2.9752-Week Range$0.90Now: $2.47▼$4.04Volume310,800 shsAverage Volume821,897 shsMarket Capitalization$200.22 millionP/E RatioN/ADividend YieldN/ABeta0.41 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aduro BioTech, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy and multiple myeloma; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and NK cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B.V.; license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingAduro BioTech has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.38, Aduro BioTech has a potential upside of 117.6% from its current price of $2.47.Amount of Analyst CoverageAduro BioTech has only been the subject of 2 research reports in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesAduro BioTech has received 456 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAduro BioTech has received 274 “underperform” votes. (Add your “underperform” vote.)Community SentimentAduro BioTech has received 62.47% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aduro BioTech and other stocks. Vote “Outperform” if you believe ADRO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADRO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAduro BioTech does not currently pay a dividend.Dividend GrowthAduro BioTech does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aduro BioTech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.90% of the stock of Aduro BioTech is held by insiders.Percentage Held by Institutions48.06% of the stock of Aduro BioTech is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aduro BioTech are expected to decrease in the coming year, from ($0.63) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aduro BioTech is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aduro BioTech is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAduro BioTech has a P/B Ratio of 4.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADRO Previous Symbol CUSIPN/A CIK1435049 Webwww.aduro.com Phone510-848-4400Debt Debt-to-Equity Ratio0.66 Current Ratio8.91 Quick Ratio8.91Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$17.26 million Price / Sales11.60 Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book4.26Profitability EPS (Most Recent Fiscal Year)($1.03) Net Income$-82,370,000.00 Net Margins-230.92% Return on Equity-101.73% Return on Assets-22.35%Miscellaneous Employees152 Outstanding Shares81,059,000Market Cap$200.22 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $2.47 -0.03 (-1.20 %) (As of 08/13/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ADRO News and Ratings via Email Sign-up to receive the latest news and ratings for ADRO and its competitors with MarketBeat's FREE daily newsletter. Aduro BioTech (NASDAQ:ADRO) Frequently Asked Questions How has Aduro BioTech's stock price been impacted by COVID-19? Aduro BioTech's stock was trading at $2.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ADRO shares have increased by 4.7% and is now trading at $2.47. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Aduro BioTech? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aduro BioTech in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Aduro BioTech. When is Aduro BioTech's next earnings date? Aduro BioTech is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Aduro BioTech. How were Aduro BioTech's earnings last quarter? Aduro BioTech Inc (NASDAQ:ADRO) announced its quarterly earnings data on Monday, May, 4th. The biotechnology company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.05. The biotechnology company earned $13.95 million during the quarter, compared to analysts' expectations of $8.81 million. Aduro BioTech had a negative return on equity of 101.73% and a negative net margin of 230.92%. View Aduro BioTech's earnings history. What price target have analysts set for ADRO? 5 Wall Street analysts have issued 12-month price targets for Aduro BioTech's shares. Their forecasts range from $3.75 to $7.00. On average, they expect Aduro BioTech's share price to reach $5.38 in the next twelve months. This suggests a possible upside of 117.6% from the stock's current price. View analysts' price targets for Aduro BioTech. Has Aduro BioTech been receiving favorable news coverage? Media coverage about ADRO stock has been trending very negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Aduro BioTech earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Aduro BioTech. Are investors shorting Aduro BioTech? Aduro BioTech saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 3,180,000 shares, an increase of 30.3% from the January 31st total of 2,440,000 shares. Based on an average daily trading volume, of 1,280,000 shares, the days-to-cover ratio is currently 2.5 days. Currently, 6.2% of the company's stock are sold short. View Aduro BioTech's Short Interest. Who are some of Aduro BioTech's key competitors? Some companies that are related to Aduro BioTech include Cara Therapeutics (CARA), Phibro Animal Health (PAHC), Dynavax Technologies (DVAX), ORIC Pharmaceuticals (ORIC), Endo International (ENDP), Trillium Therapeutics (TRIL), Provention Bio (PRVB), Vectura Group (VEGPF), Frequency Therapeutics (FREQ), Assembly Biosciences (ASMB), Nkarta (NKTX), Kadmon (KDMN), Legend Biotech (AMTI), Passage Bio (KROS) and BIOFRONTERA AG/ADR (BFRA). View all competitors. What other stocks do shareholders of Aduro BioTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aduro BioTech investors own include Regulus Therapeutics (RGLS), EXACT Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Nabriva Therapeutics (NBRV), Micron Technology (MU), Amarin (AMRN), Crispr Therapeutics (CRSP), PTC Therapeutics (PTCT) and VBI Vaccines (VBIV). Who are Aduro BioTech's key executives? Aduro BioTech's management team includes the following people: Mr. Stephen T. Isaacs, Chairman, CEO & Pres (Age 70)Dr. Andrea van Elsas, Chief Scientific Officer (Age 52)Mr. Blaine E. Templeman, Chief Admin. Officer & Chief Legal Officer (Age 53)Ms. Jennifer Lew, Chief Financial Officer (Age 46)Ms. Alexandra Santos, Exec. Director of Corp. Affairs & Investor Relations When did Aduro BioTech IPO? (ADRO) raised $119 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. What is Aduro BioTech's stock symbol? Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO." Who are Aduro BioTech's major shareholders? Aduro BioTech's stock is owned by a variety of institutional and retail investors. Top institutional investors include Goldman Sachs Group Inc. (0.29%), California Public Employees Retirement System (0.18%), Alps Advisors Inc. (0.14%), Ensign Peak Advisors Inc (0.11%), Dupont Capital Management Corp (0.06%) and SG Americas Securities LLC (0.04%). Company insiders that own Aduro BioTech stock include Blaine Templeman, Celeste Ferber, Elsas Andrea Van, Jennifer Lew, Natalie Sacks and Stephen T Isaacs. View institutional ownership trends for Aduro BioTech. Which institutional investors are selling Aduro BioTech stock? ADRO stock was sold by a variety of institutional investors in the last quarter, including Dupont Capital Management Corp, and UBS Group AG. Company insiders that have sold Aduro BioTech company stock in the last year include Blaine Templeman, Celeste Ferber, Elsas Andrea Van, and Stephen T Isaacs. View insider buying and selling activity for Aduro BioTech. Which institutional investors are buying Aduro BioTech stock? ADRO stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., California Public Employees Retirement System, Alps Advisors Inc., Ensign Peak Advisors Inc, Strs Ohio, State Board of Administration of Florida Retirement System, Virtu Financial LLC, and Wedbush Securities Inc.. View insider buying and selling activity for Aduro BioTech. How do I buy shares of Aduro BioTech? Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aduro BioTech's stock price today? One share of ADRO stock can currently be purchased for approximately $2.47. How big of a company is Aduro BioTech? Aduro BioTech has a market capitalization of $200.22 million and generates $17.26 million in revenue each year. The biotechnology company earns $-82,370,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Aduro BioTech employs 152 workers across the globe. What is Aduro BioTech's official website? The official website for Aduro BioTech is www.aduro.com. How can I contact Aduro BioTech? Aduro BioTech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected] This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
